AG˹ٷ

STOCK TITAN

[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Positive)
Form Type
4
Rhea-AI Filing Summary

On 08/04/2025, RTW Investments, LP—together with Managing Partner Dr. Roderick Wong—filed a Form 4 disclosing the purchase of 3,636,363 pre-funded warrants in Orchestra BioMed Holdings (OBIO). The warrants were acquired at $2.7499 per warrant (Transaction Code “P�) and carry a nominal exercise price of $0.0001 per share. Each warrant is immediately exercisable into one common share, but exercise is limited so total beneficial ownership does not exceed 9.99 % of OBIO’s outstanding stock.

The filing confirms RTW and Dr. Wong as >10 % shareholders and directors. Post-transaction, they hold 3.64 million derivative securities that, if fully exercised, could add an equivalent number of common shares to OBIO’s float, creating potential dilution. The warrants have no expiration date, giving the insiders flexibility on timing.

Il 08/04/2025, RTW Investments, LP—insieme al Managing Partner Dr. Roderick Wong—ha depositato un Modulo 4 comunicando l'acquisto di 3.636.363 warrant pre-finanziati in Orchestra BioMed Holdings (OBIO). I warrant sono stati acquisiti al prezzo di 2,7499 $ ciascuno (Codice Transazione “P�) e hanno un prezzo di esercizio nominale di 0,0001 $ per azione. Ogni warrant è immediatamente esercitabile per una azione ordinaria, ma l'esercizio è limitato affinché la proprietà totale non superi il 9,99 % delle azioni in circolazione di OBIO.

La comunicazione conferma RTW e il Dr. Wong come azionisti e amministratori con oltre il 10 % del capitale. Dopo la transazione, detengono 3,64 milioni di strumenti derivati che, se esercitati completamente, potrebbero aggiungere un numero equivalente di azioni ordinarie al flottante di OBIO, creando una potenziale diluizione. I warrant non hanno data di scadenza, offrendo agli insider flessibilità sui tempi di esercizio.

El 08/04/2025, RTW Investments, LP, junto con el Socio Director Dr. Roderick Wong, presentó un Formulario 4 notificando la compra de 3.636.363 warrants prefinanciados en Orchestra BioMed Holdings (OBIO). Los warrants fueron adquiridos a $2.7499 por warrant (Código de Transacción “P�) y tienen un precio nominal de ejercicio de $0.0001 por acción. Cada warrant puede ejercerse inmediatamente por una acción ordinaria, pero el ejercicio está limitado para que la propiedad total no supere el 9.99 % de las acciones en circulación de OBIO.

La presentación confirma a RTW y al Dr. Wong como accionistas y directores con más del 10 %. Tras la transacción, poseen 3,64 millones de valores derivados que, si se ejercen completamente, podrían añadir un número equivalente de acciones ordinarias al capital flotante de OBIO, generando una posible dilución. Los warrants no tienen fecha de vencimiento, lo que brinda flexibilidad a los insiders en cuanto al momento de ejercerlos.

2025� 4� 8�, RTW Investments, LP� 매니� 파트� Dr. Roderick Wong� 함께 Orchestra BioMed Holdings (OBIO)3,636,363개의 선지� 워런�� 매입했다� Form 4� 제출했습니다. 워런트는 개당 $2.7499� 취득되었으며(거래 코드 “P�), 행사가격은 주당 $0.0001� 명목가� 가집니�. � 워런트는 즉시 보통� 1주로 행사� � 있으�, � 보유 지분이 OBIO� 발행 주식� 9.99%� 초과하지 않도� 행사가 제한됩니�.

이번 제출� RTW와 Dr. Wong� 10% 이상� 주주이자 이사임이 확인되었습니�. 거래 � 이들은 364� 개의 파생 증권� 보유하게 되며, 전부 행사� 경우 OBIO� 유통 주식 수가 동등하게 증가하여 희석 효과가 발생� � 있습니다. 워런트는 만료일이 없어 내부자들� 행사 시기� 자유롭게 조절� � 있습니다.

Le 08/04/2025, RTW Investments, LP, accompagné du Managing Partner Dr. Roderick Wong, a déposé un formulaire 4 révélant l'achat de 3 636 363 bons de souscription préfinancés dans Orchestra BioMed Holdings (OBIO). Les bons ont été acquis au prix de 2,7499 $ par bon (code transaction « P ») et portent un prix d'exercice nominal de 0,0001 $ par action. Chaque bon est immédiatement exerçable contre une action ordinaire, mais l'exercice est limité afin que la détention totale ne dépasse pas 9,99 % du capital en circulation d'OBIO.

Le dépôt confirme RTW et le Dr Wong comme actionnaires et administrateurs détenant plus de 10 %. Après la transaction, ils détiennent 3,64 millions de titres dérivés qui, s'ils sont entièrement exercés, pourraient ajouter un nombre équivalent d'actions ordinaires au flottant d'OBIO, créant une dilution potentielle. Les bons n'ont pas de date d'expiration, offrant aux initiés une flexibilité quant au moment de l'exercice.

Am 08.04.2025 reichte RTW Investments, LP zusammen mit dem geschäftsführenden Partner Dr. Roderick Wong ein Formular 4 ein, in dem der Kauf von 3.636.363 vorfinanzierten Warrants an Orchestra BioMed Holdings (OBIO) offengelegt wurde. Die Warrants wurden zu je 2,7499 $ (Transaktionscode „P�) erworben und haben einen nominalen Ausübungspreis von 0,0001 $ pro Aktie. Jeder Warrant ist sofort in eine Stammaktie umwandelbar, allerdings ist die Ausübung so begrenzt, dass die Gesamtbeteiligung 9,99 % des ausstehenden Aktienkapitals von OBIO nicht überschreitet.

Die Meldung bestätigt RTW und Dr. Wong als Aktionäre und Direktoren mit mehr als 10 % Beteiligung. Nach der Transaktion halten sie 3,64 Millionen derivative Wertpapiere, die bei vollständiger Ausübung eine äquivalente Anzahl an Stammaktien zum Streubesitz von OBIO hinzufügen könnten, was zu einer möglichen Verwässerung führt. Die Warrants haben kein Ablaufdatum, was den Insidern zeitliche Flexibilität bietet.

Positive
  • Significant insider commitment: RTW and Dr. Wong invested roughly $10 M to increase exposure to OBIO.
  • Immediate exercisability: Warrants can convert at $0.0001, indicating insiders expect long-term appreciation.
Negative
  • Dilution risk: Up to 3.64 M new shares may enter the float once ownership headroom allows.
  • Ownership cap: 9.99 % limit could stagger conversions, prolonging the overhang on share supply.

Insights

TL;DR: Large insider warrant buy suggests confidence but flags future dilution risk.

The acquisition of 3.64 M pre-funded warrants by RTW and Dr. Wong increases their economic exposure to OBIO without crossing the 9.99 % cap. Paying $2.75 indicates willingness to commit ~$10 M (3.64 M × $2.7499) in fresh capital, a positive signal for investors who track insider sentiment. Because the warrants are immediately exercisable at $0.0001, conversion is effectively assured once headroom exists, potentially expanding the share count by ~6 %. Investors should weigh the bullish insider stance against the dilution overhang and monitor subsequent Form 4s for exercises.

Il 08/04/2025, RTW Investments, LP—insieme al Managing Partner Dr. Roderick Wong—ha depositato un Modulo 4 comunicando l'acquisto di 3.636.363 warrant pre-finanziati in Orchestra BioMed Holdings (OBIO). I warrant sono stati acquisiti al prezzo di 2,7499 $ ciascuno (Codice Transazione “P�) e hanno un prezzo di esercizio nominale di 0,0001 $ per azione. Ogni warrant è immediatamente esercitabile per una azione ordinaria, ma l'esercizio è limitato affinché la proprietà totale non superi il 9,99 % delle azioni in circolazione di OBIO.

La comunicazione conferma RTW e il Dr. Wong come azionisti e amministratori con oltre il 10 % del capitale. Dopo la transazione, detengono 3,64 milioni di strumenti derivati che, se esercitati completamente, potrebbero aggiungere un numero equivalente di azioni ordinarie al flottante di OBIO, creando una potenziale diluizione. I warrant non hanno data di scadenza, offrendo agli insider flessibilità sui tempi di esercizio.

El 08/04/2025, RTW Investments, LP, junto con el Socio Director Dr. Roderick Wong, presentó un Formulario 4 notificando la compra de 3.636.363 warrants prefinanciados en Orchestra BioMed Holdings (OBIO). Los warrants fueron adquiridos a $2.7499 por warrant (Código de Transacción “P�) y tienen un precio nominal de ejercicio de $0.0001 por acción. Cada warrant puede ejercerse inmediatamente por una acción ordinaria, pero el ejercicio está limitado para que la propiedad total no supere el 9.99 % de las acciones en circulación de OBIO.

La presentación confirma a RTW y al Dr. Wong como accionistas y directores con más del 10 %. Tras la transacción, poseen 3,64 millones de valores derivados que, si se ejercen completamente, podrían añadir un número equivalente de acciones ordinarias al capital flotante de OBIO, generando una posible dilución. Los warrants no tienen fecha de vencimiento, lo que brinda flexibilidad a los insiders en cuanto al momento de ejercerlos.

2025� 4� 8�, RTW Investments, LP� 매니� 파트� Dr. Roderick Wong� 함께 Orchestra BioMed Holdings (OBIO)3,636,363개의 선지� 워런�� 매입했다� Form 4� 제출했습니다. 워런트는 개당 $2.7499� 취득되었으며(거래 코드 “P�), 행사가격은 주당 $0.0001� 명목가� 가집니�. � 워런트는 즉시 보통� 1주로 행사� � 있으�, � 보유 지분이 OBIO� 발행 주식� 9.99%� 초과하지 않도� 행사가 제한됩니�.

이번 제출� RTW와 Dr. Wong� 10% 이상� 주주이자 이사임이 확인되었습니�. 거래 � 이들은 364� 개의 파생 증권� 보유하게 되며, 전부 행사� 경우 OBIO� 유통 주식 수가 동등하게 증가하여 희석 효과가 발생� � 있습니다. 워런트는 만료일이 없어 내부자들� 행사 시기� 자유롭게 조절� � 있습니다.

Le 08/04/2025, RTW Investments, LP, accompagné du Managing Partner Dr. Roderick Wong, a déposé un formulaire 4 révélant l'achat de 3 636 363 bons de souscription préfinancés dans Orchestra BioMed Holdings (OBIO). Les bons ont été acquis au prix de 2,7499 $ par bon (code transaction « P ») et portent un prix d'exercice nominal de 0,0001 $ par action. Chaque bon est immédiatement exerçable contre une action ordinaire, mais l'exercice est limité afin que la détention totale ne dépasse pas 9,99 % du capital en circulation d'OBIO.

Le dépôt confirme RTW et le Dr Wong comme actionnaires et administrateurs détenant plus de 10 %. Après la transaction, ils détiennent 3,64 millions de titres dérivés qui, s'ils sont entièrement exercés, pourraient ajouter un nombre équivalent d'actions ordinaires au flottant d'OBIO, créant une dilution potentielle. Les bons n'ont pas de date d'expiration, offrant aux initiés une flexibilité quant au moment de l'exercice.

Am 08.04.2025 reichte RTW Investments, LP zusammen mit dem geschäftsführenden Partner Dr. Roderick Wong ein Formular 4 ein, in dem der Kauf von 3.636.363 vorfinanzierten Warrants an Orchestra BioMed Holdings (OBIO) offengelegt wurde. Die Warrants wurden zu je 2,7499 $ (Transaktionscode „P�) erworben und haben einen nominalen Ausübungspreis von 0,0001 $ pro Aktie. Jeder Warrant ist sofort in eine Stammaktie umwandelbar, allerdings ist die Ausübung so begrenzt, dass die Gesamtbeteiligung 9,99 % des ausstehenden Aktienkapitals von OBIO nicht überschreitet.

Die Meldung bestätigt RTW und Dr. Wong als Aktionäre und Direktoren mit mehr als 10 % Beteiligung. Nach der Transaktion halten sie 3,64 Millionen derivative Wertpapiere, die bei vollständiger Ausübung eine äquivalente Anzahl an Stammaktien zum Streubesitz von OBIO hinzufügen könnten, was zu einer möglichen Verwässerung führt. Die Warrants haben kein Ablaufdatum, was den Insidern zeitliche Flexibilität bietet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RTW INVESTMENTS, LP

(Last) (First) (Middle)
40 10TH AVENUE, FLOOR 7

(Street)
NEW YORK NY 10014

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/04/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Pre-Funded Warrants (Right to Buy) $0.0001 08/04/2025 P 3,636,363 (1) (1) Common Stock 3,636,363 $2.7499 3,636,363 I See footnote(2)
1. Name and Address of Reporting Person*
RTW INVESTMENTS, LP

(Last) (First) (Middle)
40 10TH AVENUE, FLOOR 7

(Street)
NEW YORK NY 10014

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
WONG RODERICK

(Last) (First) (Middle)
40 10TH AVENUE, FLOOR 7

(Street)
NEW YORK NY 10014

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, together with their Attribution Parties (as defined in the Pre-Funded Warrants), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
2. Held by certain affiliated funds managed by RTW Investments, LP ("RTW"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein.
/s/ Roderick Wong, for RTW Investments, LP, By: Roderick Wong, M.D., Managing Partner 08/06/2025
/s/ Roderick Wong, By: Roderick Wong, M.D. 08/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many OBIO warrants did RTW Investments purchase on 08/04/2025?

3,636,363 pre-funded warrants were acquired.

What was the purchase price of the OBIO pre-funded warrants?

Each warrant was bought for $2.7499.

When can the OBIO warrants be exercised?

They are immediately exercisable but subject to a 9.99 % ownership limit.

What is the exercise price of the OBIO warrants?

The warrants convert to common stock at a nominal $0.0001 per share.

Do the OBIO warrants have an expiration date?

No; the filing states the warrants have no expiration date.
Orchestra BioMed Holdings Inc

NASDAQ:OBIO

OBIO Rankings

OBIO Latest News

OBIO Latest SEC Filings

OBIO Stock Data

103.18M
25.36M
21.81%
49.74%
1.46%
Biotechnology
Surgical & Medical Instruments & Apparatus
United States
NEW HOPE